Background The cyclooxygenase inhibitor ibuprofen may be used to treat patent ductus
arteriosus (PDA) in preterm infants. Whether selective early treatment of large PDAs with …

Hemodynamic support for a micropreemie is critically important for preventing mortality and
morbidity. An essential consideration in hemodynamic support is insufficient transition from …

Background The optimal treatment strategy for patent ductus arteriosus (PDA) in extremely
preterm infants is currently highly controversial. This study aimed to evaluate the association …

The Swiss Neonatal Network & Follow-up Group (SwissNeoNet) started as a paper based
standardized data collection for very preterm born infants in 1995 for the purpose of …

BACKGROUND Patent ductus arteriosus (PDA) treatment is common among very low birth
weight (VLBW) infants. Given limitations in evidence, controversy exists regarding treatment …

Objective To compare length of stay (LOS) in neonatal care for babies born extremely
preterm admitted to networks participating in the International Network for Evaluating …

Background There is inconsistent evidence suggesting the clinical relevance of the early
detection of future needs of preterm patent ductus arteriosus (PDA) surgery. We tested the …

Infants born very prematurely with patent ductus arteriosus (PDA) are at increased risk for
bronchopulmonary dysplasia (BPD) and mortality. 1, 2 Surgical ligation is used less …

Congenital heart disease (CHD) represents a group of abnormalities present at birth, and a
relevant cause of perinatal mortality. Infertility is a recurrent condition in medical practice …

Patent ductus arteriosus (PDA) is associated with neonatal morbidities in high-risk preterm
infants. Early neonatal treatment by ibuprofen induces the ductus arteriosus (DA) closure in …